

INDEX

A

- Active principle of endotoxin 17
- Acyl chain fluidity 33, 42
- Adjuvant 2, 3, 71, 83, 85, 92, 101, 103, 111-120, 125, 126, 129
- Aggregate structure 25, 27-30, 32, 33, 42-45
- Albumin 41, 42, 69, 71
- Animal model 3, 71, 72, 76, 84, 86, 101, 105, 108, 125, 126, 128
- Antagonist 12, 18, 31, 32, 41, 43, 69, 76, 83, 91
- Antitumoral activity 102, 104, 106

B

- Bactericidal/Permeability-Increasing Protein 40, 42, 45, 70
- B cell 2, 53, 56
- Biosynthetic precursor to lipid a 6, 7
- Blood cytokine 126

C

- C3H/HeJ 54, 59
- Cancer 83-86, 92, 93, 101-103, 111, 112, 113, 115-120, 125-129, 133, 134
- Cancer immunotherapy 119, 125
- Cancer vaccine 83, 85, 92, 111-113, 115-120
- Cathelicidin 40, 45, 46
- CD14 2, 34, 39-41, 43, 45, 46, 53, 55, 59, 70, 87, 88, 91, 92, 134
- Chemical synthesis 1, 6, 17, 18, 69
- Clinical toxicity 127
- Colorectal cancer 112, 113, 117, 126
- Critical micellar concentration 25, 26
- Cytokine 28, 30, 32, 34, 42, 43, 45, 46, 56, 59, 60, 62, 63, 70, 71, 73-76, 81-85, 88-90, 92, 101, 102, 105, 107, 111, 119, 125-129, 133

D

- D-Glucosamine 2-amino-2-deoxy-d-glucose (GlcN) 5-11, 14-16, 31
- Dendritic cell 53, 56, 62, 63, 71, 84, 107, 111, 120, 126, 133, 134

E

- Endotoxic principle 5, 25, 33, 39
- Endotoxin 1, 5, 9, 17, 25, 27, 30, 32-34, 36, 39, 41, 42, 46, 53, 56, 59, 82-85, 88-90, 92, 126, 128, 129

F

- Free lipid A 8, 9, 27, 28, 30, 41

G

- Gel to liquid crystalline phase transition 44
- GlcN3N (3-dideoxy-d-glucose) 8, 11, 14-16
- Glycolipid 5, 8, 17

H

- Heat shock protein 33, 54, 75
- Hydrophilic backbone 5, 6, 8, 15, 16

K

- Kdo (3-deoxy-d-manno-octulosonic acid) 9, 14, 18, 27, 41, 44

L

- Lactoferrin 42, 44, 70
- Leptospira interrogans* 15, 54
- Lipid A 9, 12-17, 25-27, 32, 33, 39, 41, 42, 44, 46, 53, 54, 59, 65, 69, 70, 72, 73, 75, 81-83, 85, 86, 91, 101, 111, 133
- Lipid bilayer 5, 117
- Lipid X 7

Lipopolysaccharide (LPS) 1, 2, 5-9, 12, 14, 18, 19, 25, 27-34, 39-46, 53-56, 59, 60, 62-64, 69, 70, 72-75, 81-92, 101, 102, 104, 111, 119, 125-129, 133
Lipopolysaccharide-binding protein (LBP) 2, 31, 33, 34, 36, 39-41, 43-46, 53, 59, 70, 91, 134
Lipoprotein 40, 42-44, 69

M

Mass spectrometry (MS) 6, 16, 19
Molecular conformation 12, 25, 27, 29, 31, 32
Molecular modelling 25, 31
Monophosphoryl lipid A (MPL) 28, 29, 32, 69-72, 82, 83, 85, 91, 92, 103, 111-114, 117-120, 126, 127
MyD88 59-65, 87, 88, 91, 92

N

NFκB 72, 87
Nuclear magnetic resonance spectroscopy (NMR) 6, 16, 17, 19

P

Pharmacokinetic 86, 128
Polar substituent 13-15, 19
Primary acyl group 6, 8, 9, 11, 17
Proteasome 63, 90-92

R

RP105 53, 56

S

SDZ MRL 953 72, 83, 85, 86, 92, 103, 127, 128
Secondary acyl group 6, 8, 9, 11, 12, 16, 17
Sepsis 39, 41, 69, 81-84, 86
Supramolecular structure 3, 25, 28, 32, 43, 45

T

Taxol 54
T cell 2, 133
TIRAP 61-63
TLR2 54, 62, 87, 88, 91, 92, 134
TLR4 2, 3, 33, 34, 40, 41, 53-56, 59-65, 69, 70, 72, 87-89, 91, 92, 111, 113, 133, 134
Tolerance 3, 62, 63, 69, 72-74, 81-93, 105-107, 117, 126, 128, 129, 134
Toll-like receptor (TLR) 2, 33, 40, 53, 59-65, 87, 91, 134
Toll receptor 2, 54
TRAM 61-63
TRIF 60-64
Tumor 1, 2, 25, 39, 54, 69-76, 82-86, 92, 101-108, 111-120, 125-129, 133, 134
Tumor associated antigens (TAA) 111-113, 115-117, 119, 120
Tumor growth 71, 73-75, 84, 102-107, 118, 126, 127, 129
Tumor immunity 117, 125

U

Unsaturated acyl group 12, 18